-transparent.png){kind=logo}
Substituted 8-ethyl-2-(2-oxo-1,2-dihydroindol-3-ylidene)-8-hydroxy-2,3,5,8- tetrahydro-6-oxa-3a-azacyclopenta[b]naphthalene-1,4,7-triones were synthesized and evaluated as topoisomerase I inhibitors in an in vitro cleavable complex assay. The activity of these compounds may be attributed to their rigid, planar geometry, and an attempt was made to correlate the SAR in this series to known attributes of camptothecin.
Related Publications
K Lackey, and
J M Besterman, and
W Fletcher, and
P Leitner, and
B Morton, and
D D Sternbach
April 1994,
Hematology/oncology clinics of North America,
K Lackey, and
J M Besterman, and
W Fletcher, and
P Leitner, and
B Morton, and
D D Sternbach
May 2009,
Expert opinion on therapeutic patents,
K Lackey, and
J M Besterman, and
W Fletcher, and
P Leitner, and
B Morton, and
D D Sternbach
January 2003,
Current topics in medicinal chemistry,
K Lackey, and
J M Besterman, and
W Fletcher, and
P Leitner, and
B Morton, and
D D Sternbach
December 2007,
ChemMedChem,
K Lackey, and
J M Besterman, and
W Fletcher, and
P Leitner, and
B Morton, and
D D Sternbach
August 1998,
Pharmacy world & science : PWS,
K Lackey, and
J M Besterman, and
W Fletcher, and
P Leitner, and
B Morton, and
D D Sternbach
August 2018,
Molecular cancer therapeutics,
K Lackey, and
J M Besterman, and
W Fletcher, and
P Leitner, and
B Morton, and
D D Sternbach
June 2012,
Journal of enzyme inhibition and medicinal chemistry,
K Lackey, and
J M Besterman, and
W Fletcher, and
P Leitner, and
B Morton, and
D D Sternbach
September 1995,
Mutation research,
K Lackey, and
J M Besterman, and
W Fletcher, and
P Leitner, and
B Morton, and
D D Sternbach
January 1997,
Journal of computer-aided molecular design,
K Lackey, and
J M Besterman, and
W Fletcher, and
P Leitner, and
B Morton, and
D D Sternbach
September 2004,
Cancer research,
